Decoding the Architecture of Modern Drug Development with Dr. Lloyd Klickstein

The complex journey from a laboratory hypothesis to a life-saving medication is a process defined as much by economic strategy and regulatory hurdles as it is by scientific innovation. In a recent episode of The Peter Attia Drive, Dr. Lloyd Klickstein, a physician-scientist with over two decades of experience at the forefront of biotechnology and academic medicine, provided a comprehensive analysis of the modern drug development arc. Klickstein, whose career spans from foundational research at Harvard Medical School to leadership roles at pharmaceutical giant Novartis and the founding of Versanis Bio, offers a rare, behind-the-scenes look at how the medical industry identifies, engineers, and validates novel therapeutics.

The Evolution of a Physician-Scientist

Dr. Klickstein’s trajectory reflects the shift in 21st-century medicine toward translational research—the process of bridging the gap between bench-top discoveries and bedside applications. Following his medical and doctoral training at Harvard and clinical specialization in rheumatology at Brigham and Women’s Hospital, Klickstein spent over a decade in academia. However, he transitioned to industry to address what he identifies as a critical bottleneck in medicine: the failure to effectively translate high-potential research into viable patient treatments.

At Novartis, Klickstein helped pioneer the "New Indication Discovery Unit," an organizational structure designed to repurpose existing molecules or accelerate the development of drugs for conditions where the medical need remained unmet. This shift from pure academic inquiry to industrial application underscores a broader trend in biotechnology, where capital allocation and regulatory strategy are as vital to success as the underlying molecular biology.

The Mechanics of Drug Discovery: A Case Study in Bimagrumab

To illustrate the rigor of drug development, Klickstein points to the trajectory of bimagrumab, a monoclonal antibody he helped develop while at Versanis Bio—a company later acquired by Eli Lilly for a valuation of up to $1.925 billion. Initially designed to combat muscle atrophy by targeting the myostatin and activin signaling pathways, the drug’s development path took a non-linear turn during clinical trials.

The research team observed that while bimagrumab successfully increased lean muscle mass, it simultaneously induced significant reductions in body fat. This unexpected finding necessitated a pivot in the drug’s development strategy. By identifying this "secondary" effect early, researchers were able to reposition bimagrumab as a candidate for treating obesity, potentially in tandem with GLP-1 agonists like semaglutide. This case study serves as a masterclass in the necessity of agility within pharmaceutical development; the ability to identify "failures" or "unexpected outcomes" and pivot toward a new therapeutic indication can determine the difference between a stalled project and a market-leading innovation.

The Economic and Regulatory Landscape

A central theme of the discussion is the staggering cost and time associated with bringing a new drug to market. The average cost to develop a new prescription drug, including the failures of candidate compounds, is often estimated to be between $1 billion and $2.5 billion, with timelines spanning 10 to 15 years. Klickstein identifies several factors contributing to these figures:

1. Capital Allocation: Developing a drug requires sustained, high-risk investment over a decade or more. Investors must balance the potential for "quantum steps" in medical treatment against the high probability of clinical trial failure.
2. Regulatory Hurdles: The submission of an Investigational New Drug (IND) application is only the beginning of a process that requires rigorous adherence to Good Manufacturing Practice (GMP) standards. Regulatory bodies like the FDA require extensive data to ensure safety, efficacy, and batch-to-batch consistency.
3. Patent Protections: Intellectual property acts as the engine for this investment. Patents provide a limited window of exclusivity, which is necessary for companies to recoup the massive R&D costs before generic or biosimilar competition enters the market.

Klickstein argues that the pharmaceutical industry must approach non-oncology diseases with the same level of urgency often reserved for cancer. He posits that many chronic conditions currently managed with palliative approaches could potentially be reversed or halted if the same "ambition" and resource intensity were applied to their discovery phases.

Advancing the Frontier: mTOR and Cancer Prevention

The conversation concludes by shifting toward the cutting edge of longevity science: the role of mTOR (mechanistic target of rapamycin) inhibition. Klickstein, having co-led landmark trials on mTOR and immunosenescence, discusses how modulating this pathway may help address the decline in immune function associated with aging.

Current research in this field is moving beyond traditional disease management toward "geroprotection"—the attempt to delay the onset of age-related systemic decline. Klickstein’s current work at Koslapp Therapeutics, where he serves as President and CEO, focuses on novel pharmacologic approaches to cancer prevention. This represents a significant pivot from reactive medicine (treating established tumors) to proactive, preventive medicine (intercepting the biological conditions that allow cancer to thrive).

Implications for the Future of Medicine

The insights provided by Klickstein highlight a critical evolution in the medical field. The days of serendipitous drug discovery are increasingly being replaced by data-driven, systematic engineering. However, the human element remains paramount. The success of a therapeutic program is heavily dependent on the judgment of the scientists who must decide when to "kill" a failing project to preserve capital for more promising leads, and when to push forward in the face of initial data ambiguity.

For patients and healthcare providers, understanding this process is essential for navigating the hype that often surrounds new drug breakthroughs. The rigorous, often tedious, reality of the drug development arc—clinical trials, regulatory filings, manufacturing challenges, and economic viability—is the filter through which all medical progress must pass.

As we look toward the future, the integration of new modalities, such as gene therapies and advanced biologics, promises to expand the scope of treatable diseases. Yet, as Klickstein’s career illustrates, the fundamental requirements for success remain unchanged: a deep understanding of human biology, the willingness to pivot based on clinical evidence, and the structural support to move an idea from a lab bench to a pharmacy shelf.

Summary of Key Phases in the Drug Development Arc

• Target Identification: Identifying a biological pathway (e.g., myostatin) that, if modulated, will yield a clinical benefit.
• Engineering and Screening: Developing a modality—whether a small molecule or a biologic (like an antibody)—that interacts with the target specifically and safely.
• Preclinical Testing: Assessing toxicity and efficacy in animal models to determine whether a compound is suitable for human exposure.
• Clinical Trials (Phase I-III): Moving through safety studies (Phase I), dose-finding and initial efficacy (Phase II), and large-scale validation (Phase III).
• Regulatory Approval: Compiling the massive datasets generated throughout the process for review by bodies such as the FDA or EMA.
• Post-Market Surveillance: Monitoring the drug’s performance in the general population to detect rare side effects or secondary benefits, as seen in the evolution of bimagrumab.

By demystifying these steps, Klickstein emphasizes that while the pharmaceutical industry is often criticized for its costs and complexity, it is also the primary engine for the most significant health improvements in human history. The challenge for the next generation of physician-scientists is to increase the efficiency of this pipeline, ensuring that promising ideas reach patients faster and more reliably.